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Abstract. 
 
Through direct interaction with the voltage-
dependent anion channel (VDAC), proapoptotic mem-
 
bers of the Bcl-2 family such as Bax and Bak induce
 
apoptogenic cytochrome 
 
c
 
 release in isolated mitochon-
dria, whereas BH3-only proteins such as Bid and Bik
do not directly target the VDAC to induce cytochrome
 
c
 
 release. To investigate the biological signiﬁcance of
the VDAC for apoptosis in mammalian cells, we pro-
duced two kinds of anti-VDAC antibodies that inhib-
ited VDAC activity. In isolated mitochondria, these an-
tibodies prevented Bax-induced cytochrome 
 
c
 
 release
and loss of the mitochondrial membrane potential
 
(
 
Dc
 
), but not Bid-induced cytochrome 
 
c
 
 release. When
microinjected into cells, these anti-VDAC antibodies,
but not control antibodies, also prevented Bax-induced
cytochrome 
 
c
 
 release and apoptosis, whereas the anti-
bodies did not prevent Bid-induced apoptosis, indicat-
ing that the VDAC is essential for Bax-induced, but not
Bid-induced, apoptogenic mitochondrial changes and
apoptotic cell death. In addition, microinjection of
these anti-VDAC antibodies signiﬁcantly inhibited eto-
poside-, paclitaxel-, and staurosporine-induced apopto-
sis. Furthermore, we used these antibodies to show that
Bax- and Bak-induced lysis of red blood cells was also
mediated by the VDAC on plasma membrane. Taken
together, our data provide evidence that the VDAC
plays an essential role in apoptogenic cytochrome 
 
c 
 
re-
lease and apoptosis in mammalian cells.
Key words: VDAC • apoptosis • Bcl-2 • Bax • cyto-
chrome 
 
c
 
Introduction
 
Apoptosis is a gene-regulated mechanism of cell death
that is essential for elimination of unwanted cells in vari-
ous biological systems in most metazoans. Apoptosis is
driven by a family of cysteine proteases called caspases,
which process various cellular proteins to execute apop-
totic cell death (for review see Thornberry and Lazebnik,
1998). The Bcl-2 family of proteins are well-characterized
regulators of apoptosis, consisting of three distinct sub-
families (for reviews see Adams and Cory, 1998; Green
 
and Reed, 1998; Tsujimoto and Shimizu, 2000a,b). (a)
The Bcl-2 subfamily contains antiapoptotic proteins, such
 
as Bcl-2 and Bcl-x
 
L
 
, which show sequence homology at the
Bcl-2 homology (BH)
 
1
 
 1, BH2, and BH3 domains, as well
as at the BH4 domain in most cases. (b) The Bax subfam-
ily contains proapoptotic proteins, such as Bax and Bak,
which show sequence homology at BH1, BH2, and BH3.
(c) BH3-only proteins are another subfamily of proapop-
totic proteins that only share homology at the BH3 do-
main, such as Bid, Bik, and Bim. It has been shown that in
addition to BH1 and BH2, the BH4 domain is required for
the antiapoptotic activity of Bcl-2 and Bcl-x
 
L
 
, whereas the
BH3 domain of proapoptotic proteins is essential, and suf-
ficient, for proapoptotic activity (for reviews see Adams
and Cory, 1998; Tsujimoto and Shimizu, 2000a,b). Many of
the proapoptotic members of the Bcl-2 family (such as
Bax, Bid, Bim, and Bad) are localized in the cytoplasm of
living cells, but during apoptosis, translocate to the mito-
chondria through various modifications of these proteins,
such as proteolytic cleavage and dephosphorylation, prob-
ably leading to conformational changes (for review see
Tsujimoto, 1998).
Mitochondria play a crucial role in apoptosis by releas-
 
ing several apoptogenic molecules, including cytochrome 
 
c
 
and Smac/Diablo from the intermembrane space into the
cytoplasm in response to a variety of death-promoting
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stimuli (for reviews see Adams and Cory, 1998; Green and
Reed, 1998; Du et al., 2000; Tsujimoto and Shimizu,
2000a,b; Verhagen et al., 2000). Once
 
 
 
in the cytoplasm, cy-
tochrome 
 
c
 
 binds to Apaf-1, triggering oligomerization of
the Apaf-1/cytochrome 
 
c
 
 complex that leads to recruit-
ment and activation of a major apical caspase, caspase-9.
In turn, caspase-9 activates various effector caspases such
as caspase-3 (for review see Thornberry and Lazebnik,
1998). It has been shown that Bcl-2 family proteins regu-
late mitochondrial membrane permeability to control cy-
tochrome 
 
c
 
 release: proapoptotic Bax, Bak, and BH3-only
proteins like Bid and Bik induce cytochrome 
 
c
 
 release,
whereas antiapoptotic Bcl-2 and Bcl-x
 
L
 
 prevent it (Eskes
et al., 1998; Jürgensmeier et al., 1998; Marzo et al., 1998;
Narita et al., 1998; Finucane et al., 1999; Pastorino et al
 
.
 
,
1999; Shimizu and Tsujimoto, 2000).
Recently, we have shown that Bax/Bak and Bcl-x
 
L
 
, but
not Bik and Bid, can bind directly to the voltage-dependent
anion channel (VDAC) and modulate its activity (Shimizu
et al., 1999, 2000a,b; Shimizu and Tsujimoto, 2000). The
VDAC is a mitochondrial outer membrane channel, which
usually functions as the pathway for the movement of vari-
ous substances in and out of the mitochondria (for review
see Colombini, 1989), and is considered to be a component
of the oligoprotein permeability transition (PT) pore com-
plex that plays a role in the PT (for reviews see Bernardi et
al., 1994; Zoratti and Szabó, 1995). Our biochemical and
electrophysical studies have shown that Bax and Bak en-
hance VDAC activity so that cytochrome 
 
c
 
 passes through
the channel, whereas Bcl-x
 
L
 
 closes the VDAC (Shimizu et
al., 1999, 2000a,b; Shimizu and Tsujimoto, 2000). We have
also shown that nonfunctional mutants of Bax and Bcl-x
 
L
 
lose their effect on VDAC activity (Shimizu et al., 1999,
2000a,b). Furthermore, Bax/Bak induces apoptotic mito-
chondrial changes, including cytochrome 
 
c
 
 release and mi-
tochondrial membrane potential (
 
Dc
 
) loss, in mitochondria
isolated from wild-type yeast, but not VDAC1-deficient
yeast (Shimizu et al., 1999). We have also shown that Bax
expression induces cytochrome 
 
c
 
 release in wild-type yeast
cells, but not in VDAC1-deficient yeast cells (Shimizu et al.,
2000c). Based on these findings, we have proposed that the
VDAC plays an essential role in Bax/Bak-induced apop-
totic mitochondrial changes and thus in the process of apop-
tosis in mammalian cells (Shimizu et al., 1999, 2000a,b), al-
though no direct evidence has been available. Other models
for apoptogenic cytochrome 
 
c
 
 release have also been pro-
posed. Cytochrome 
 
c
 
 release might be mediated by physical
rupture of outer membrane resulting from mitochondrial
swelling (Vander Heiden et al., 1997) or destabilization of
membrane induced by Bax as well as tBid (Basanez et al.,
1999; Kudla et al., 2000). Alternatively, Bax and Bak form
oligomer channels in membrane that are permeable to cyto-
chrome 
 
c
 
, and tBid facilitates the insertion into the mito-
chondrial membrane or oligomerization of Bax and Bak
(Eskes et al., 2000; Saito et al., 2000; Wei et al., 2000).
Microinjection of specific antibodies into cells has
proven very useful to analyze the biological functions of
particular proteins (Imamoto et al
 
.
 
, 1995; Hieda et al.,
1999). Therefore, we generated anti-VDAC antibodies
that blocked VDAC activity, and showed that Bax-
induced, but not Bid-induced, cytochrome 
 
c
 
 release and
apoptosis were significantly inhibited by these antibodies,
and that these antibodies also significantly inhibited eto-
 
poside-, paclitaxel-, and staurosporine-induced apoptosis.
These results provide evidence that the VDAC plays an
essential role in apoptotic mitochondrial changes and ap-
optosis in mammalian cells.
 
Materials and Methods
 
Chemicals
 
A monoclonal antibody for pigeon denatured cytochrome 
 
c 
 
(65981A used
for Western blot analysis) and an antibody for pigeon native cytochrome 
 
c
 
(65971A used for immunostaining), both of which cross-reacted with hu-
man and rat cytochrome 
 
c
 
, were purchased from BD PharMingen. An
anti–human VDAC monoclonal antibody (31HL) and an anti–human Bax
polyclonal antibody (N20) were obtained from Calbiochem and Santa Cruz
Biotechnology, Inc., respectively. An anti-Tom20 polyclonal antibody was
kindly provided by Prof. K. Mihara (Kyushu University, Fukuoka, Japan).
[
 
14
 
C]sucrose and [
 
3
 
H]glucose were purchased from Amersham Pharmacia
Biotech. Other chemicals were obtained from Wako Biochemicals.
 
Protein Purification
 
Recombinant human Bax (rBax) was expressed as a His-tagged protein in
 
Escherichia coli 
 
strain XL1-blue using the Xpress System (Invitrogen), as
described elsewhere (Narita et al., 1998). Irrelevant control proteins were
prepared using the empty vector. Recombinant human Bid, truncated Bid
(tBid), Bik, and Bak
 
D
 
C (lacking the COOH-terminal 21 amino acid resi-
dues) were expressed as GST fusion proteins in 
 
Escherichia coli 
 
strain
DH5
 
a
 
 and were purified on a glutathione-Sepharose column. Then Bid,
tBid, Bik, and Bak
 
D
 
C were released from GST by cleavage with thrombin.
The purity of Bax, Bid, tBid, Bik, and Bak
 
D
 
C was shown to be 
 
.
 
80%. All
purified proteins were finally dissolved in the same control buffer composed
of 20 mM Hepes-K
 
1
 
, pH 7.4, and 1 mM dithiothreitol. Rat liver mitochon-
drial VDAC was purified as described previously previously (Shimizu et al.,
1999), and showed a single band on SDS-polyacrylamide gel.
 
Generation of Anti-VDAC Antibodies
 
Two oligopeptides corresponding to parts of the human VDAC1 were
synthesized on a Multiple Peptide Synthesizer (model 396; Advanced
Chemtech) using diisopropylcarbodiimide/1-hydroxybenzotriazole-acti-
vated fluorenylmethoxycarbonyl-protected amino acids. The purity of
each peptide was determined to be 
 
.
 
90% by matrix-assisted laser desorp-
tion ionization time of flight mass spectrometry. These peptides were used
to immunize rabbits, as described elsewhere (Imamoto et al., 1992). Anti-
VDAC antibodies raised against the two oligopeptides (designated as
Ab#20 and Ab#25) were purified from rabbit serum on a column of
Sepharose conjugated with purified rat VDAC. Antibodies that bound to
VDAC-Sepharose were eluted with 0.1 M glycine-HCl (pH 2.5) and neu-
tralized with NaOH. We used three different preparations of Ab#25
(Ab#25-1, 25-2, and 25-3) that came from different animals, but mainly
used Ab#25-1 unless otherwise mentioned.
To remove antiseptic, the antibodies were dialyzed extensively against
a buffer composed of 20 mM Hepes-K
 
1
 
 (pH 7.4), and then were concen-
trated in a Micro Centricon 30 (Amicon Corp.) for use in microinjection
and mitochondrial experiments.
 
Immunoprecipitation and Western Blot Analysis
 
Bax–VDAC interactions in the presence of anti-VDAC antibodies or con-
trol IgG were assessed by coimmunoprecipitation, as described elsewhere
(Shimizu et al., 1999) using rat liver mitochondria. The mitochondria were
lysed and immunoprecipitated with an anti-Bax antibody (N20) and the
amount of coimmunoprecipitated VDAC was estimated by Western blot
analysis. Interaction between rBax and VDAC on RBCs was also assessed
by coimmunoprecipitation as described (Shimizu et al., 1999).
 
Reconstitution of VDAC and Bax in Liposomes
 
Plain liposomes and VDAC liposomes were prepared as described else-
where (Shimizu et al., 1999). Liposomes in buffer consisting of 30 mM so-
dium sulfonate and 20 mM Tricine-NaOH (pH 5.3) were preincubated
with 0.2 
 
m
 
g/
 
m
 
l antibodies for 3 min at room temperature, and with rBax
(0.2 
 
m
 
g/
 
m
 
l) or the equivalent amount of irrelevant protein. VDAC activi-
ties were measured by assessing [
 
14
 
C]sucrose uptake, as described previ-
ously (Shimizu et al., 1999). In brief, 20 
 
m
 
l of liposomes treated with anti- 
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bodies was incubated with 5 
 
m
 
l of [
 
14
 
C]sucrose (97%, 200 
 
m
 
Ci/ml) in the
presence of rBax or irrelevant protein at 25
 
8
 
C, and filtered by centrifuga-
tion using a 30K limiting filter (Millipore) to remove free [
 
14
 
C]sucrose.
Then the [
 
14
 
C]sucrose incorporated into the liposomes was measured with
a gamma-scintillation counter (model 1414; Wallac). Bax liposomes and
irrelevant protein liposomes were prepared at pH 7.4 by the same proce-
dure as VDAC liposomes, using the same amount of rBax as VDAC pro-
tein or an equivalent amount of irrelevant protein. Bax channel activity
was measured by the same radiotracer uptake procedure, except that
[
 
3
 
H]glucose (97%, 20 
 
m
 
Ci/ml) was used instead of [
 
14
 
C]sucrose.
 
Preparation of Isolated Mitochondria
 
Livers from male Donryu rats were homogenized with a glass Teflon Pot-
ter homogenizer. Mitochondria were isolated in 0.3 M mannitol, 10 mM
potassium Hepes (pH 7.4), 0.2 mM EDTA, and 0.1% fatty acid–free BSA
(MT-1 medium), as described previously (Shimizu et al., 1998). Then the
mitochondria were washed twice with the same medium without EDTA
(MT-2 medium).
 
Measurement of Mitochondrial
Biochemical Parameters
 
For energization, isolated mitochondria (1 mg protein/ml) were incubated
at 25
 
8
 
C in MT-2 medium plus 1 mM potassium phosphate and 4.2 mM suc-
cinate, unless otherwise indicated. Mitochondria were incubated with an-
tibodies for 5 min, and then were treated with rBax, rBid, or Ca
 
2
 
1
 
 at the
indicated concentrations, after which 
 
Dc
 
 and cytochrome 
 
c
 
 release were
measured. 
 
Dc
 
 was assessed by measuring the 
 
Dc
 
-dependent uptake of
rhodamine 123 using a spectrophotometer (F-4500; Hitachi), as described
elsewhere (Shimizu et al., 1998). For detection of cytochrome 
 
c
 
 release
and mitochondrial association of Bax, mitochondria were spun, and the
pellet and supernatant were subjected to Western blot analysis using anti-
cytochrome 
 
c 
 
and anti-Bax antibodies. Mitochondrial respiration was
measured using an O
 
2
 
 electrode in the presence of succinate (state IV) or
succinate plus ADP (state III). 
 
Dc
 
 of cells was measured by incubating
cells with 1 
 
m
 
M JC-1, followed by examination under a fluorescence mi-
croscope (IX70; Olympus).
 
Microinjection
 
HeLa cells (a human cervical cancer cell line) were maintained in RPMI
1640 medium supplemented with 10% fetal bovine serum. Microinjection
experiments were performed using a micromanipulator (Narishige), es-
sentially as described previously (Hieda et al., 1999). Maximum and mini-
mum injected volume were calculated to be 1.7
 
 3
 
 10
 
2
 
14
 
 and 1.7 
 
3
 
 10
 
2
 
15
 
 li-
ters (Matsuoka et al., 1994). Thus, when 12 
 
m
 
g/
 
m
 
l of antibody was injected,
the injected amount was estimated to be 0.2–0.02 pg. 1 h after injection of
antibodies (free from antiseptic) with or without Cy5-labeled mouse IgG
into the cytoplasm of cells, rBax or rtBid with or without green fluores-
cent protein (GFP) was injected in the cytoplasm of the same cells. The
concentrations of proteins used for microinjection are described in the fig-
Figure 1. Inhibition of
VDAC activity by anti-
VDAC antibodies. (A) Puta-
tive model of human
VDAC1 topology. The
epitopes of the three anti-
VDAC antibodies (Ab#20,
Ab#25, and 31HL) are
shown by boxes. (B) Speci-
ficity of Ab#20 and Ab#25.
Rat liver mitochondria (Mt)
lysate (15 mg) and HeLa cell
lysate (10 mg) were subjected
to Western blotting using
Ab#20 and Ab#25. (C) Inhi-
bition of both VDAC activity
and Bax-induced enhance-
ment of VDAC activity by
Ab#20 and Ab#25. 20 ml of
plain liposomes or VDAC li-
posomes was incubated with
0.2 mg/ml of the indicated an-
tibodies for 3 min, and then
were incubated with 5 ml of
[14C]sucrose (97%; 200 mCi/
ml) in the presence (black
bar) or absence (white bar)
of rBax (0.2 mg/ml) at 258C
for the 6 min. The [14C]su-
crose incorporated into the
liposomes was measured as
described in Materials and
Methods. Data are shown as
the mean 6 SD for three in-
dependent experiments. (D)
Lack of influence of Ab#25
on Bax channel activity. Ir-
relevant control protein lipo-
somes and Bax liposomes were incubated with 0.2 mg/ml of Ab#25 or NRI for 5 min, and then incubated with 5 ml of [3H]glucose (97%;
20 Ci/mmol) at 258C for 5 min. The [3H]glucose incorporated into the liposomes was measured as described in Materials and Methods.
Data are shown as the mean 6 SD for three independent experiments. 
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ure legends. In some experiments, cells were stained with Hoechst 33342
(10 
 
m
 
M) or annexin V–Cy3 using an Annexin V–Cy3 apoptosis detection
kit (MBL). Cell morphology was examined under a transmission micro-
scope or a fluorescence microscope.
 
Immunostaining
 
Cells were washed twice with PBS and fixed with 3.7% formaldehyde in
PBS at room temperature for 10 min. After permeabilization with 0.5%
Triton X-100 at room temperature for 5 min, cells were incubated with
 
5% skim milk. Then the primary antibody in 5% skim milk was added for
 
z
 
12 h at 4
 
8
 
C. After washing twice, cells were treated with the respective
secondary antibody conjugated with Alexafluor488 or 568 and were exam-
ined under a fluorescence microscope.
 
Lysis of RBCs
 
Whole blood was obtained from a healthy donor with consent. RBCs were
prepared by washing the whole blood with a large amount of 0.9% NaCl,
followed by centrifugation and suspending in 0.9% NaCl. The RBCs were
Figure 2. Inhibition of Bax-
induced  Dc loss and cytochrome
c release in isolated mitochon-
dria by anti-VDAC antibodies.
(A) Inhibition of Bax-induced
Dc loss by Ab#20 and Ab#25.
Mitochondria (1 mg/ml) were
preincubated with or without 0.6
mg/ml of the indicated antibodies
(Ab#20, Ab#25, 31HL, or NRI)
for 5 min, after which rBax (0.2
mg/ml) was added. Then Dc was
measured from the rhodamine
123 (Rh123) uptake over 25
min. When Dc dropped,
rhodamine 123 was released, re-
sulting in an increase of
rhodamine 123 intensity. Com-
plete loss of Dc was demon-
strated by incubation of the
mitochondria with 1 mM
carbonylcyanide m-chlorophe-
nylhydrazone (CCCP, protono-
phore). Data are representative
of three independent experi-
ments. (B) Inhibition of Bax-
induced cytochrome c release by
Ab#20 and Ab#25. Mitochon-
dria (1 mg/ml) were preincu-
bated with or without the
indicated concentrations of
antibodies (Ab#20, Ab#25-1,
Ab#25-2, 31HL, or NRI) for 5
min, after which rBax (0.2 mg/
ml) or Ca21 (50 mM) was added
(top 5 panels). Mitochondria
preincubated with antibodies
were also incubated with rBax in
the presence of 0.2 mM EGTA
(bottom panel). In the presence
of EGTA, a higher concentra-
tion of rBax (1 mg/ml) was used
to induce cytochrome c release
comparable to that without
EGTA. The extent of cyto-
chrome  c release was measured at 10 min (second, third, fifth, and bottom panels) or at the indicated times (top and fourth panels) by
Western blot analysis of the supernatants. “Total” represents the total amount of cytochrome c in the same amount of mitochondria.
Data are representative of two or three independent experiments. (C) Immunostaining of mitochondria with Ab#25. Mitochondria (1
mg/ml) were incubated with Ab#25 (open circles) or NRI (filled circle) at the indicated concentrations, and then stained with anti–rabbit
IgG-Alexa488, after which the fluorescence was measured by flow cytometry as described in Materials and Methods. Data are shown as
the mean 6 SD for three independent experiments. (D) Lack of effect of Ab#20 and Ab#25 on mitochondrial respiration. Mitochondria
(1 mg/ml) were incubated with 0.6 mg/ml of the indicated antibodies for 5 min, and then respiration was measured in the presence of 5
mM succinate (state IV; white bars) or succinate plus 0.3 mM ADP (state III; black bars). Data are representative of two independent
experiments. (E) Lack of effect of Ab#20 and Ab#25 on mitochondrial association of Bax. Mitochondria were treated as described in A.
At 10 min after addition of rBax, the mitochondria were spun, and the supernatants (sup) and pellets (pt) were subjected to Western
blot analysis for Bax detection. (F) Lack of effect of Ab#25 on Bax–VDAC interaction. Mitochondria were treated as described in A.
At 10 min after addition of rBax, mitochondria were lysed and immunoprecipitated with anti-Bax antibody (a-Bax) or NRI. Immune
complexes were analyzed by Western blotting. “Total” represents 1/10 the amount of mitochondria used for the experiment.Shimizu et al. Essential Role of VDAC in Apoptosis 241
treated with antibodies or BH4 oligopeptides for 5 min, after which rBax,
rBak, or Kanagawa hemolysin was added at the indicated amount. Then
the RBCs were spun, and released hemoglobin was measured by the ab-
sorbance at 543 nm (the isospecific point of reduced and oxidized hemo-
globin) using a spectrophotometer (UV-160A; Shimadzu).
FACS® Analysis
Mitochondria and RBCs were incubated with antibodies at the indicated
concentrations for 30 min at 48C, and then washed with MT-1 medium and
0.9% NaCl, respectively. Subsequently, the mitochondria and RBCs were
incubated with 20 mg/ml of anti–rabbit IgG-Alexa488 for 1 h at 48C. After
washing twice, samples were applied to a flow cytometer (FACSCali-
bur™; Becton Dickinson) for analysis. 
Results
Anti-VDAC Antibodies Inhibit Bax-induced Dc Loss 
and Cytochrome c Release in Isolated Mitochondria
Recently, we showed that Bax/Bak is able to induce cyto-
chrome c release by opening the VDAC through direct in-
teraction in a proteoliposome system (Shimizu et al., 1999,
2000a). However, the essential role of the VDAC in apop-
totic cytochrome c release and cell death in mammalian
cells was still unconfirmed. For this purpose, we produced
anti-VDAC antibodies that could inhibit VDAC activity.
As epitopes, we selected two oligopeptides (amino acids
104–120 and 151–165) of human VDAC1 shown in Fig. 1
A, based on previous observations that VDAC in intact bo-
vine heart mitochondria is cleaved by trypsin at lysine resi-
dues between arginine108, which corresponds to lysine108 in
human VDAC1, and arginine119 and by chymotrypsin at
the tyrosine117 and tyrosine172 residues (De Pinto and Pal-
mieri, 1992), indicating that these sites are probably ex-
posed to the cytoplasm, and also based on the proposed
three-dimensional structure (De Pinto and Palmieri, 1992;
Song and Colombini, 1996) that suggests that these oli-
gopeptides are probably localized near the entrance of
the channel whereas most of the other regions form one
a-helix and 12 b-strands that cross the membrane to create
a b-barrel (Fig. 1 A). Furthermore, since these residues are
well conserved among three isoforms of human and mouse,
the antibodies were expected to react with all isoforms of
various mammals. Both antibodies raised in rabbits (Ab#20
recognizing amino acids 151–165 and Ab#25 recognizing
amino acids 104–120) were affinity purified and were
shown to be highly specific for human and rat VDAC (Fig.
1 B). As shown in Fig. 1 C, Ab#20 and Ab#25, but not nor-
mal rabbit IgG (NRI), efficiently inhibited VDAC activity,
as assessed by [14C]sucrose uptake into VDAC liposomes.
Ab#25 and Ab#20, but not NRI, also inhibited the Bax-
induced enhancement of VDAC activity (Fig. 1 C). In con-
trast, both Ab#20 and Ab#25 showed no effect on Bax
channel activity, as assessed by [3H]glucose uptake into
Bax liposomes (Fig. 1 D; data not shown).
Using these neutralizing anti-VDAC antibodies, we first
examined the role of the VDAC in Bax-induced apoptotic
changes of isolated mitochondria. As shown in Fig. 2, A
and B (third panel from the top) NRI and a monoclonal
anti-VDAC antibody (31HL: with an epitope correspond-
ing to the NH2-terminal region of VDAC as shown in Fig. 1
A) (Babel et al., 1991) that had no influence on VDAC ac-
tivity (Benz et al., 1992; data not shown) did not inhibit, but
rather slightly enhanced both Bax-induced Dc loss and
cytochrome c release. In contrast, these mitochondrial
changes were efficiently inhibited by Ab#20 and Ab#25 in a
Figure 3. Effect of the mi-
croinjection of anti-VDAC
antibodies. (A) Localiza-
tion of injected Ab#25.
HeLa cells were microin-
jected with 3 mg/ml of
Ab#25. After fixing, the
cells were incubated with
anti-cytochrome  c antibody
for 12 h at 48C, and then
with anti–rabbit IgG-
Alexa488 (which reacted
with Ab#25) and anti–
mouse IgG-Alexa568 (which
reacted with anti-cyto-
chrome  c antibody), fol-
lowed by observation under
a fluorescence microscope.
(B) Lack of inhibition of mi-
tochondrial respiration by
Ab#25. HeLa cells were mi-
croinjected with 12 mg/ml of
Ab#25. Then noninjected and injected cells were incubated in glucose-containing (1 glc) or glucose-free (2 glc) medium in the pres-
ence or absence of 10 mM oligomycin (oligo). After 24 h, cells were stained with JC-1 dye and observed under a fluorescence micro-
scope. The dye gave an orange color to cells with a high Dc and a green color to cells with a low Dc.The Journal of Cell Biology, Volume 152, 2001 242
Figure 4. Inhibition of rBax-induced apoptosis by injection of anti-VDAC antibodies. (A) Induction of apoptosis by microinjection of
rBax. rBax (1 mg/ml) or the equivalent amount of irrelevant control protein was microinjected into the cytoplasm of HeLa cells with
GFP (3 mg/ml). After 8 h, cell morphology was assessed by transmission microscopy (TM) and fluorescence microscopy (GFP). Cells
were also stained with annexin V and Hoechst 33342, and observed under a fluorescence microscope. The color photographs were
taken from the same field. The arrowhead indicates an example of cells at the terminal stage of apoptosis, showing weak annexin V
staining with no Hoechst 33342 staining. (B–E) Inhibition of rBax-induced apoptosis by microinjection of Ab#20 and Ab#25. (B) HeLaShimizu et al. Essential Role of VDAC in Apoptosis 243
concentration-dependent manner (Fig. 2, A and B, top
three panels), indicating that the VDAC is required for
Bax-induced cytochrome c release and Dc loss in mamma-
lian mitochondria under our experimental conditions, con-
sistent with our previous findings in yeast mitochondria
(Shimizu et al., 1999, 2000c). The amount of Ab#20 and
Ab#25 used was near the saturation level for VDAC on the
mitochondria, as judged from flow cytometric analysis of
mitochondria stained with Ab#25 (Fig. 2 C) and also by
comparing the amount of each antibody with the amount of
VDAC in the mitochondria using PAGE (data not shown).
Since we have previously shown that Bax-induced cyto-
chrome c release largely depends on mitochondrial respi-
ration under our experimental conditions (Shimizu and
Tsujimoto, 2000), and since VDAC is involved in mito-
chondrial respiration (for review see Colombini, 1989) by
acting as a gate for respiratory substrates, the possibility
was raised that the anti-VDAC antibodies inhibited respi-
ration and thereby blocked the action of Bax on the mito-
chondria. However, as shown in Fig. 2 D, Ab#20 and
Ab#25 had no effect on state IV and state III respiration at
concentrations sufficient to inhibit cytochrome c release,
suggesting that these antibodies inhibited cytochrome c re-
lease by directly inhibiting Bax-induced enhancement of
VDAC activity. Since neither Bax association with the mi-
tochondria nor Bax–VDAC interaction was inhibited by
Ab#20 and Ab#25 (Fig. 2, E and F), inhibition of apoptotic
mitochondrial changes by these antibodies was not due to
simple blocking of Bax association with mitochondria or
Bax–VDAC interaction, but was probably due to inhibi-
tion of VDAC conformational changes that are normally
induced by Bax.
As can be seen in Fig. 2 B (forth and fifth panels from
the top), Ca21-induced cytochrome c release, which was
previously shown to be mediated by the PT (Narita et al.,
1998), was also inhibited by Ab#20 and Ab#25 (25-1 and
25-2 were derived from different animals), indicating that
the VDAC is essential for the PT.
It has previously been shown that Bax-induced cyto-
chrome c release is largely dependent on the PT (i.e.,
blocked by PT inhibitors such as cyclosporine A and
bongkrekic acid, and accompanied by Dc loss) (Jürgens-
meier et al., 1998; Marzo et al., 1998; Narita et al., 1998)
and only partly occurs in a PT-independent manner (Nar-
ita et al., 1998; Shimizu and Tsujimoto, 2000), although
other groups have reported that Bax-induced cytochrome
c release is not dependent on the PT, particularly in the
absence of Ca21 (Eskes et al., 1998; Finucane et al., 1999;
Kluck et al., 1999). To determine whether inhibition of
Bax-induced cytochrome c release by Ab#20 and Ab#25
was specific to PT-associated cytochrome c release, we ex-
amined the effect of these antibodies on Bax-induced cy-
tochrome c release in the presence of a Ca21 chelator that
completely inhibited the PT (Zoratti and Szabó, 1995; data
not shown). As shown in Fig. 2 B (bottom), PT-indepen-
dent cytochrome c release induced by Bax was also inhib-
ited by both Ab#20 and Ab#25, indicating an essential role
of the VDAC in Bax-induced cytochrome c release re-
gardless of PT dependency. Note that a higher concentra-
tion of rBax was used to induce cytochrome c release in
the presence of EGTA than that without EGTA.
Anti-VDAC Antibodies Inhibit Bax-induced Apoptosis
To determine whether the VDAC had an essential role in
Bax-induced apoptosis in mammalian cells, we carried out
an experiment in which Ab#20 and Ab#25 were microin-
jected into the cytoplasm of HeLa cells. Consistent with
the predominant localization of VDAC in the mitochon-
dria, Ab#25 was mainly observed in the mitochondria by
immunostaining, when injected at a lower concentration (3
mg/ml) (Fig. 3 A), whereas it was observed in the mito-
chondria with a small amount throughout the cytoplasm
when injected at a higher concentration of 12 mg/ml (data
not shown), suggesting that a concentration of 3 mg/ml was
less than the saturation level for mitochondrial VDAC.
Therefore, microinjection experiments were mainly done
with Ab#20 and Ab#25 at 12 mg/ml, which was close to the
saturation level for mitochondrial VDAC. Injection of
these antibodies showed little toxicity in HeLa cells (data
not shown). To test the effect of Ab#20 and Ab#25 on mi-
tochondrial respiration, cells were incubated in glucose-
free medium for 24 h. Since glycolysis was halted under
these conditions, inhibition of mitochondrial respiration
(e.g., by the addition of oligomycin, an F1 ATPase inhibi-
tor) led to mitochondrial Dc loss (Fig. 3 B, second panel).
However, when cells were microinjected with Ab#20 or
Ab#25, Dc remained high during incubation in glucose-
free medium (Fig. 3 B, far right panel; data not shown), in-
dicating that these antibodies did not significantly affect
mitochondrial respiration, consistent with the results ob-
tained using isolated mitochondria (Fig. 2 D).
To examine the effect of Ab#20 and Ab#25 on Bax-
induced apoptosis, these antibodies or NRI (as a control)
were microinjected into the cytoplasm of HeLa cells, and
rBax was microinjected into the cytoplasm of the same
cells 1 h later to induce apoptosis. After injection of rBax,
but not irrelevant protein, nearly all NRI-injected cells un-
derwent apoptosis at 15 h as shown by cellular shrinkage,
cells were microinjected with 12 mg/ml of the indicated antibodies. After 1 h, 2 mg/ml of rBax was microinjected into the same cells, and
after 15 h, cells were examined under a transmission microscope. All of the cells shown were microinjected. Data are representative of
seven independent experiments. (C) The same procedure shown in B was followed, except that 3 mg/ml of GFP was coinjected with
rBax. Cell morphology was assessed at the indicated times under a fluorescence microscope. Data are representative of three indepen-
dent experiments. (D) HeLa cells were microinjected with Ab#20 (filled squares), Ab#25 (filled circles), or NRI (open circles) at the in-
dicated concentrations. After 1 h, rBax at the indicated concentrations was microinjected into the same cells, and apoptosis was investi-
gated under a transmission microscope. More than 100 injected cells were analyzed. Data are representative of two or seven
independent experiments. (E) HeLa cells were microinjected with 12 mg/ml of the indicated antibodies. After 1 h, the cells were injected
with 1 mg/ml of rBax, and apoptosis was assessed at 12 h under a transmission microscope. NMI indicates normal mouse IgG used as a
control for 31HL. Data are representative of two independent experiments.The Journal of Cell Biology, Volume 152, 2001 244
rounding (Fig. 4 A), and eventual detachment from the
culture dishes. Apoptosis was also confirmed by positive
annexin V staining and by nuclear shrinkage and fragmen-
tation on Hoechst 33342 staining (Fig. 4 A). Cells in the
terminal stage of apoptosis (Fig. 4 A, arrowhead) only
showed weak staining with annexin V and lost most of
their DNA. On the other hand, depending on the amount
of rBax injected (1 or 2 mg/ml), the majority and nearly
half of the cells, respectively, remained alive after being
preinjected with Ab#20 or Ab#25 (Fig. 4 D, left and mid-
dle), as shown by their flat morphology (Fig. 4 B) and by
the division of some cells within 24 h (data not shown). In-
hibition of apoptosis after injection of Ab#20 and Ab#25
was also confirmed by lack of annexin V staining as well as
a normal nuclear morphology on Hoechst 33342 staining
(data not shown). Fig. 4 C shows time-lapse photographs
of cells injected with Ab#25 or NRI and then with rBax (1
mg/ml) and recombinant GFP (rGFP) to identify injected
cells: NRI-injected cells shrank and became fragmented
after 3 h, and were detached from the culture dishes by 12 h,
whereas these changes were not observed when Ab#20
or Ab#25 was preinjected. Incomplete inhibition of rBax
(2 mg/ml)-induced apoptosis by Ab#20 and Ab#25 at 12
mg/ml (Fig. 4 D, middle) was probably due to degradation
of injected antibodies, because intracellular concentra-
tions of Ab#20 and Ab#25, as assessed by immunostaining
with anti–rabbit antibody conjugated with Alexa568, sig-
nificantly decreased in a time-dependent manner (75 and
40% at 12 and 24 h after injection, respectively) and be-
cause injection of Ab#25 at a little higher concentration,
18 mg/ml, nearly completely inhibited Bax-induced apopto-
sis (Fig. 4 D, right). The inhibitory effect of these antibod-
ies on Bax-induced apoptosis was not observed at lower
concentrations of the antibodies, although the antibodies
could still inhibit apoptosis induced by a lower concentra-
tion of rBax (data not shown). To exclude the possibility
that these antibodies inhibited Bax-induced apoptosis
merely by nonspecific binding to the mitochondria, we
tested other antibodies, including 31HL and an antibody
specific to Tom20, a protein on mitochondrial outer mem-
brane. Both of these other antibodies did not inhibit Bax-
induced apoptosis (Fig. 4 E). These results indicated that
the VDAC is essential for Bax-induced apoptosis in mam-
malian cells.
Anti-VDAC Antibodies Inhibit Bax-induced 
Cytochrome c Release in Cells
To test whether Ab#20 and Ab#25 inhibited rBax-induced
cytochrome c release from mitochondria in cells, Cy5-IgG
was coinjected together with Ab#20 or Ab#25 to identify
injected cells, followed by injection of rBax, and the distri-
bution of cytochrome c was examined in comparison with
that of mitochondrial F1 ATPase. In cells injected with
NRI and rBax, cytochrome c was diffusely distributed at
12 h, and in some cells, it was mainly localized in the nu-
cleus (Fig. 5), and mitochondria tended to come together
in the cells, as defined by F1 ATPase staining. Thus the dis-
tribution of cytochrome c was quite different from that of
F1 ATPase as seen better in a merged photograph (Fig. 5,
top right), indicating that cytochrome c had been released
from the mitochondria. On the other hand, in cells in-
jected with Ab#25 and rBax, the distribution of cyto-
chrome c and F1 ATPase was almost completely concor-
dant (Fig. 5), as is the case in healthy cells (data not
shown), indicating that Bax-induced cytochrome c release
was prevented by Ab#25. Virtually identical results were
obtained with Ab#20 (data not shown). These results indi-
cated that the VDAC is essential for Bax-induced cyto-
chrome c release in mammalian cells.
Effect of Anti-VDAC Antibodies on other Forms
of Apoptosis
We next tested the effect of Ab#20 and Ab#25 on other
forms of apoptosis. We have recently shown that BH3-
only proteins, such as Bid (also tBid, an active form with
an NH2-terminal truncation) and Bik, do not bind to the
VDAC, suggesting that a non-VDAC mechanism is in-
Figure 5. Inhibition of rBax-induced cytochrome c release by anti-VDAC antibodies. HeLa cells were microinjected with 12 mg/ml of
NRI or Ab#25 plus 0.4 mg/ml of Cy5-mouse IgG (to identify the injected cells), and then 1 mg/ml of rBax was injected. After 12 h, the in-
tracellular distribution of cytochrome c and that of F1 ATPase (as a mitochondrial marker) was assessed by immunostaining. Fluores-
cence images of cytochrome c and F1 ATPase are merged in the right panels (overlay).Shimizu et al. Essential Role of VDAC in Apoptosis 245
Figure 6. Inhibition of VP16-, paclitaxel- and staurosporine-induced, but not rtBid-induced, apoptosis by anti-VDAC antibodies. (A) Lack of
inhibition of Bid- and Bik-induced cytochrome c release from isolated mitochondria by Ab#20 and Ab#25. Mitochondria (1 mg/ml) were pre-
incubated with or without 0.6 mg/ml of the indicated antibodies (Ab#20, Ab#25, NRI, or 31HL) for 5 min, and then rBid (0.2 mg/ml) or rBik
(0.2 mg/ml) was added. Cytochrome c release was measured at the indicated times (top two panels) or at 10 min (bottom panel) by Western
blot analysis of supernatants obtained after centrifugation to remove the mitochondria. “Total” represents the total amount of cytochrome c
in the same amount of mitochondria. Data are representative of two independent experiments. (B and C) Lack of effect of Ab#20 and Ab#25
on tBid-induced apoptosis. HeLa cells were microinjected with 12 mg/ml of Ab#25 (B; filled circles in C), Ab#20 (filled squares in C), or NRI
(B; open circles in C). After 1 h, 2 mg/ml (C, left) or 0.5 mg/ml (B; C, right) of rtBid was microinjected into the same cells, and apoptosis was as-
sessed from the cell morphology. More than 100 injected cells were analyzed. Data are representative of three independent experiments. Rep-
resentative photographs taken at 12 h are shown in B. All cells shown in B were microinjected. (D–G) Inhibition of VP16-, paclitaxel-, and
staurosporine-induced apoptosis by microinjection of Ab#25 and Ab#20. HeLa cells were microinjected with 12 mg/ml (D and E, left; F, and
G) and 18 mg/ml (E, right) of antibodies together with 3 mg/ml of GFP. After 1 h, 200 mM of VP16 (D and E), 0.3 mM of paclitaxel (F), or 2 mM
of staurosporine (G) was added. HeLa cells were also injected only with GFP as living cell control (no treatment in D). At 18 h, cells were
stained with 1 mM Hoechst 33342 (Ho342), and photographed (D). In E–G, apoptosis was assessed from the cell morphology by fluorescence
microscopy. More than 100 injected cells were analyzed. The open circles, filled circles, and filled squares correspond to NRI, Ab#25, and
Ab#20, respectively. Data are representative of two or three independent experiments.The Journal of Cell Biology, Volume 152, 2001 246
Figure 7. Inhibition of rBax-induced
release of hemoglobin from RBCs by
addition of anti-VDAC antibodies.
(A–D) Detection of VDAC on the
RBC plasma membrane. (A) RBCs,
at 0.25% (vol/vol), were incubated
with 0.4 mg/ml of Ab#25 or NRI for 30
min. After washing twice, anti–rabbit
IgG-Alexa488 was added to the cells
for 30 min and then the RBCs were
analyzed using a flow cytometer. (B)
Whole lysates of RBCs (40 mg) and
HeLa cells (3 mg) were subjected to
Western blot analysis using anti-
VDAC antibody (31HL and Ab#25)
and anticytochrome c antibody. (C
and D) RBCs (40 ml), at 15% (vol/
vol), were incubated with (1) or
without (2) 1% trypsin for 1 h at
258C, followed by incubation with 3%
trypsin inhibitor for 30 min (C).
RBCs were also incubated with an
equivalent volume of distilled water
(D.W.1) to produce ghost RBCs or
0.9% NaCl (D.W.2) for 30 min (D).
After brief centrifugation, half of
trypsin-treated RBCs and ghost RBC
lysates were subjected to Western
blot analysis using anti-VDAC anti-
body (31HL) and anti-GPDH anti-
body. (E) Interaction of rBax with
VDAC on RBCs. RBCs (100 ml), at
15% (vol/vol), were incubated with
50 mg of rBax for 15 min at 258C.
Then, RBCs were lysed and immuno-
precipitated with anti-Bax antibody
(a-Bax), anti-VDAC antibody
(31HL) (a-VDAC), NRI, or normal
mouse IgG. Immune complexes were
analyzed by Western blotting. “To-
tal” represents 1/10 the amount of ly-
sates used for the experiment. (F–H)
Inhibition of Bax- and Bak-induced
release of hemoglobin from RBCs by
Ab#20 and Ab#25. All data are indi-
cated as mean 6 SD for three inde-
pendent experiments. (F) RBCs, at
2.5% (vol/vol), were preincubated for
5 min with Ab#25 (filled circles), or
NRI (open circles) at 0.8 mg/ml, or
were preincubated without antibodies (open triangles), and then were incubated with rBax (1 mg/ml). RBCs were also incubated
with an equivalent amount of irrelevant protein (open squares) for the indicated times. Then, the RBCs were spun, and free hemo-
globin was detected at OD543 using a spectrophotometer. The total hemoglobin content was estimated after hypotonic lysis of
RBCs (filled triangle). (G) A similar procedure as described in F was performed with the indicated concentrations of Ab#20 (filled
squares), Ab#25 (filled circles), or NRI (open circles) for 5 min, followed by incubation with rBax (1 mg/ml) for 1 h. The total he-
moglobin content was estimated after hypotonic lysis of RBCs (filled triangle). (H) A similar procedure as described in F was per-
formed with Ab#25 (black bars), or NRI (white bars) for 5 min at 0.8 mg/ml, followed by incubation with rBak (1 mg/ml) or an
equivalent amount of irrelevant protein for 1 h. Free hemoglobin was assessed. (I) Flow cytometric analysis of RBCs stained with
Ab#25. RBCs, at 2.5% (vol/vol), were incubated with Ab#25 (open circles) or NRI (filled circle) at the indicated concentrations,
and then stained with anti–rabbit IgG-Alexa488. Fluorescence was measured by flow cytometry as described in Materials and
Methods. Data are indicated as mean 6 SD for three independent experiments. (J) Inhibition of Bak-induced release of hemoglo-
bin from RBCs by Bcl-xL BH4 peptide. A similar procedure as described in H was performed with the BH4 peptide (open circles)
or BH4 mutant DFL peptide (filled circles) for 5 min at the indicated concentrations, followed by incubation with rBak (1 mg/ml)
for 1 h. Data are indicated as mean 6 SD for three independent experiments. (K) Lack of effect of Ab#20 and Ab#25 on hemo-
lysin-induced release of hemoglobin from RBCs. RBCs, at 2.5% (vol/vol), were preincubated with Ab#20, Ab#25, or NRI at 0.8 mg/
ml for 5 min, and then were incubated with Kanagawa (K) hemolysin at the indicated concentrations for 1 h. Free hemoglobin was
detected at OD543 using a spectrophotometer. The total hemoglobin content was estimated after hypotonic lysis (filled triangle).
Data are indicated as mean 6 SD for three independent experiments.Shimizu et al. Essential Role of VDAC in Apoptosis 247
volved in Bid/Bik-induced cytochrome c release and cell
death (Shimizu and Tsujimoto, 2000). Consistently, addi-
tion of Ab#20 or Ab#25 did not inhibit rBid- and rBik-
induced cytochrome c release from isolated mitochondria
(Fig. 6 A, compare with Fig. 2 B). Similar results were ob-
tained with rtBid (data not shown). Furthermore, rtBid-
induced apoptosis was not inhibited by preinjection of
Ab#20 or Ab#25 into HeLa cells, irrespective of the in-
jected amount of tBid (Fig. 6, B and C). The fact that the
onset of apoptosis induced by 0.5 mg/ml of rtBid (Fig. 6 C)
was slower than that induced by 2 mg/ml of rBax (Fig. 4 D)
excluded the possibility that the amount of rtBid used sup-
plied a death signal that overwhelmed the inhibitory ca-
pacity of Ab#25. These findings, taken together with our
previous results (Shimizu and Tsujimoto, 2000), indicated
that the VDAC is not required for tBid-induced cyto-
chrome c release and cell death. Failure of Ab#20 and
Ab#25 to inhibit tBid-induced cytochrome c release and
apoptosis also indicated that inhibition of Bax-induced ap-
optosis and cytochrome c release by the anti-VDAC anti-
bodies was not due to a nonspecific effect.
When incubated with isolated mitochondria, lysates of
VP16 (etoposide)-induced apoptotic HeLa cells induce cy-
tochrome c release that is largely dependent on Bax (No-
mura et al., 1999), suggesting that Bax plays an important
role in VP16-induced cytochrome c release. As expected,
VP16-induced apoptosis was significantly inhibited by mi-
croinjection of Ab#20 or Ab#25, but not by NRI (Fig. 6, D
and E). Note that in the Ab#25-injection experiment
shown in Fig. 6 D, most of the cells that were not injected
with the antibody died of apoptosis. Although VP16 might
have activated not only Bax but also some of the BH3-
only proteins that do not target the VDAC, incomplete in-
hibition of VP16-induced apoptosis by Ab#20 or Ab#25
(Fig. 6 E, left) was largely due to degradation of antibod-
ies, because injection of Ab#25 at 18 mg/ml more efficiently
inhibited VP16-induced apoptosis (Fig. 6 E, right). We
also found that paclitaxel-induced and staurosporine-
induced apoptosis were significantly inhibited by microin-
jection of Ab#20 or Ab#25 (12 mg/ml), but not by NRI
(Fig. 6, F and G). Since paclitaxel-induced apoptosis was
reported to depend on Bim, one of the BH3-only proteins
(Bouillet et al., 1999), this suggested that Bim might target
the VDAC or that Bax/Bak may contribute to this form of
apoptosis in HeLa cells.
Anti-VDAC Antibodies Inhibit Bax-induced Lysis 
of RBCs
It has previously been reported that addition of rBax in-
duces lysis of RBCs, and this hemolysis has been consid-
ered to be due to formation of the Bax channel on the
RBC membrane (Antonsson et al., 1997). Since VDAC is
also known to be located on the plasma membrane (Cole
et al., 1992; Buettner et al., 2000), the possibility was raised
that Bax-mediated RBC lysis was also mediated by the
VDAC. The presence of the VDAC on RBC plasma mem-
brane was confirmed by flow cytometry (Fig. 7 A), which
also showed that it was oriented with the epitope for
Ab#25 facing outside, consistent with previous observa-
tions (Cole et al., 1992). Since RBCs do not possess mito-
chondria, which was confirmed by the absence of cyto-
chrome c (Fig. 7 B), and since they have no ER and Golgi
apparatus, the VDAC shown by Western blotting (Fig. 7
B) probably largely represented VDAC on the plasma
membrane. The VDAC on RBCs was z1 kD smaller than
that in HeLa cells (Fig. 7 B), but reacted with all the anti-
VDAC antibodies (31HL, Ab#25 [Fig. 7 B], Ab#20, and an
antibody whose epitope was amino acids 177–192 [data not
shown]), and, therefore, the VDAC on RBCs probably
represents a splicing variant or is subjected to RBC-spe-
cific modifications. Several erythrocyte-specific alterations
of proteins have been reported, for example, hexokinase
and pyruvate kinases (Lacrinique et al., 1992; Murakami
and Piomelli, 1997). The possibility was not excluded that
the VDAC on RBCs represents a protein highly related to
VDAC or another member of the VDAC family. The
presence of the VDAC on RBC plasma membrane was
also confirmed by tryptic digestion of VDAC but not glyc-
eraldehyde 3-phosphate dehydrogenase (GPDH), a cyto-
solic glycolytic enzyme (Fig. 7 C), and by the presence of
VDAC in ghost RBCs (Fig. 7 D). Like mitochondrial
VDAC, VDAC in RBCs bound to rBax (Fig. 7 E).
When RBCs were treated with rBax, hemolysis took
place as shown by the release of hemoglobin (Fig. 7 F),
whereas addition of Ab#20 or Ab#25 (but not NRI) effi-
ciently inhibited Bax-induced hemolysis in a dose-depen-
dent manner (Fig. 7, F and G). Consistent results were also
observed when rBak was used instead of Bax (Fig. 7 H).
These data, together with our previous observation that
Bax/Bak directly and functionally interact with VDAC, in-
dicated that Bax/Bak targeted the VDAC on the RBC
plasma membrane to induce hemolysis, although the pos-
sibility was not formally excluded that Bax/Bak acted on
RBCs independent of VDAC to trigger hemolysis that
was somehow regulated by VDAC. The amount of Ab#20
and Ab#25 used was less than would have saturated the
VDAC sites on RBCs, as judged by flow cytometric analy-
sis (Fig. 7 I). Since we have previously shown that VDAC
activity is inhibited by the BH4 peptide of Bcl-2 and Bcl-xL
(Shimizu et al., 2000b), we also tested the effect of the
BH4 peptide on Bak-induced hemolysis. As shown in Fig.
7 J, the BH4 peptide, but not a mutant BH4 peptide (DFL)
lacking the ability to close VDAC (Shimizu et al., 2000b),
inhibited hemolysis in a dose-dependent manner, although
to a lesser extent comparing with Ab#20 and 25. This par-
tial inhibition of Bax-induced hemolysis by the BH4 pep-
tide was partly due to toxicity of the BH4 peptide to in-
duce extensive aggregation that was prominent at higher
concentrations (Fig. 7 J).
As shown in Fig. 7 K, neither Ab#20 nor Ab#25 inhib-
ited hemolysis induced by Kanagawa hemolysin, which is
known to occur via formation of pores by the hemolysin it-
self. These results indicated that, as in the mitochondria,
Bax increased plasma membrane permeability by acting
on the VDAC.
Discussion
We have previously shown that Bax/Bak and Bcl-xL bind
to the VDAC and modulate its activity: Bax and Bak en-
hance/open the VDAC so that cytochrome c can pass
through the channel and Bcl-xL closes it (Shimizu et al.,
1999, 2000a). Mutational studies have indicated that the
ability of Bax/Bak and Bcl-xL to regulate apoptosis paral-The Journal of Cell Biology, Volume 152, 2001 248
lels their ability to modulate the VDAC (Shimizu et al.,
1999, 2000a,b; Shimizu and Tsujimoto, 2000). These re-
sults, taken together with our observation that Bax/Bak is
able to induce cytochrome c release and Dc loss in mito-
chondria isolated from wild-type yeast cells but not from
VDAC1-deficient yeast cells (Shimizu et al., 1999, 2000c),
led us to propose that cytochrome c is released through
the VDAC during apoptosis and the Bcl-2 family of pro-
teins regulate apoptosis by modulating VDAC activity in
mammalian cells. Several other models have been pro-
posed to explain how Bax induces cytochrome c release:
(a) by rupture of the outer mitochondrial membrane due
to swelling (Vander Heiden et al., 1997, 1999) that could
result from Bax–adenine nucleotide translator (ANT) in-
teraction (Marzo et al., 1998) or due to Bax-mediated de-
stabilization of the lipid membrane (Basanez et al., 1999);
or (b) via the multimeric channels of Bax (Eskes et al.,
2000; Saito et al., 2000). In this study, using neutralizing
anti-VDAC antibodies, we obtained direct evidence that
the VDAC is essential for Bax-induced apoptotic mito-
chondrial changes (including cytochrome c release and Dc
loss) and for apoptotic death of mammalian cells. We also
showed that anti-VDAC antibodies could significantly in-
hibit etoposide-, paclitaxel-, and staurosporine-induced
apoptosis. These results support our model that the
VDAC is involved in apoptogenic cytochrome c release
and apoptosis that are dependent on members of the Bax
subfamily. Although the results in this study confirmed
that VDAC is essential for Bax-induced apoptosis, they
did not formally confirm that cytochrome c indeed passes
through VDAC in mammalian cells during apoptosis.
However, our previous demonstration that cytochrome c
can pass through the VDAC in the presence of Bax/Bak in
the proteoliposome system (Shimizu et al., 1999, 2000a)
strongly suggests that VDAC is a channel for apoptotic cy-
tochrome c release in mammalian cells. To confirm this
notion requires further investigation. Since our neutraliz-
ing anti-VDAC antibodies inhibited VDAC activity, lead-
ing to the inhibition of apoptotic mitochondrial changes
and cell death, our results excluded the possibility that the
VDAC needs to be inhibited for the induction of apopto-
sis, leading to hyperpolarization and subsequent mito-
chondrial swelling (Vander Heiden et al., 1997, 1999) that
is blocked by the action of Bcl-2 to maintain VDAC func-
tion (Vander Heiden et al., 2000). We also showed that the
VDAC is essential for Bax-induced rupture of RBCs, al-
though this phenomenon was previously considered to be
mediated by large pores formed by Bax alone (Antonsson
et al., 1997). Thus, the VDAC is essential for Bax to mod-
ulate membrane permeability at two independent sites,
the mitochondrial membrane and the plasma membrane,
further supporting the idea that the VDAC is the func-
tional target of Bax. Given that none of the Bcl-2 family
proteins is secreted, a Bax-mediated increase of plasma
membrane permeability does not seem to be physiologi-
cally relevant. However, the VDAC on the plasma mem-
brane is involved in cell volume regulation (Thinnes et al.,
2000), so there might be secreted protein(s) that modulate
this VDAC in a similar fashion to Bax/Bak.
It has previously been suggested that Bax induces cyto-
chrome c release via two different mechanisms in isolated
mitochondria: a mechanism that is accompanied by Dc
loss and is blocked by PT inhibitors such as cyclosporine A
(Jürgensmeier et al., 1998; Marzo et al., 1998; Narita et al.,
1998) or a mechanism that is not accompanied by Dc loss
and is resistant to PT inhibitors (Eskes et al., 1998; Finu-
cane et al., 1999; Kluck et al., 1999), although it seems
likely that the former mechanism is more physiologically
relevant because Bax induces cytochrome c release to-
gether with Dc loss in mammalian cells (Xiang et al., 1996;
Marzo et al., 1998; Pastorino et al., 1998; Shimizu and
Tsujimoto, 2000; our unpublished observations). In the
present study, our neutralizing anti-VDAC antibodies in-
hibited Bax-induced cytochrome c release that was largely
PT inhibitor-sensitive. Importantly, the same antibodies
inhibited Bax-induced cytochrome c release in the absence
of Ca21, that was PT inhibitor resistant. Thus, irrespective
of PT dependence, Bax-induced cytochrome c release al-
ways requires the VDAC (Fig. 8). Accordingly, the likely
scenario is that Bax triggers VDAC opening and cyto-
chrome c release, leading to opening of inner membrane
channel(s) such as ANTs via a mutual interaction that re-
sults in Dc loss and the PT, which might subsequently in-
duce another phase of cytochrome c release.
The VDAC has been considered to be a component of
the PT pore (for reviews see Bernardi et al., 1994; Zoratti
and Szabó, 1995), although conclusive evidence for direct
involvement of the VDAC in the PT has not been ob-
tained. Our result that anti-VDAC antibodies inhibited
the Ca21-induced PT is the first direct evidence that the
VDAC is essential for the PT. Possible mutual interaction
among different components of the PT pore complex
could explain how the ANT inhibitor bongkrekic acid
(which is assumed to close the ANT channel) and cy-
Figure 8. Functional interaction of Bcl-2/Bcl-xL
and Bax/Bak, but not Bid/Bik, with the VDAC.
Bax/Bak directly opens the VDAC to induce cyto-
chrome  c release, while Bcl-2/Bcl-xL closes this
channel. Bid/Bik does not interact with the VDAC,
but probably has the ability to open an unidentified
channel(s) that is involved in cytochrome c release.
The VDAC is a component of the PT pore, which
contains ANT and cyclophilin D (CyD) and would
explain the concomitant induction of Dc loss by
Bax/Bak and inhibition of Bax/Bak-induced cyto-
chrome c and Dc loss by PT inhibitors. Bcl-2/Bcl-xL
inhibits Bid/Bik-induced cytochrome c release,
probably through heterodimerization with Bid/Bik
or by closing an unidentified channel(s).Shimizu et al. Essential Role of VDAC in Apoptosis 249
closporine A (which targets mitochondrial cyclophilin D)
can prevent Bax/Bak-induced VDAC opening and thereby
inhibit cytochrome c release (Fig. 8).
We have previously shown that Bax-induced apoptotic
mitochondrial changes are largely dependent on mito-
chondrial respiration (Shimizu and Tsujimoto, 2000). Var-
ious respiratory substrates and products, including succi-
nate and adenine nucleotides, pass through the VDAC
(for review see Colombini, 1989). Our finding that the
neutralizing anti-VDAC antibodies blocked cytochrome c
release, but not respiration, suggests that only a small frac-
tion of VDAC activity is sufficient for respiration although
a larger fraction is required for apoptogenic cytochrome c
release, or that the antibodies may not close the mitochon-
drial VDAC completely so that substances involved in res-
piration still pass through the channel.
We have previously shown that BH3-only proteins such
as Bid (also tBid) and Bik do not bind to VDAC (Shimizu
and Tsujimoto, 2000). We have also shown that Bid/Bik-
induced cytochrome c release is substantially different
from Bax/Bak-induced cytochrome c release: (a) Bax/Bak-
induced, but not Bid/Bik-induced, cytochrome c release is
accompanied by Dc loss; and (b) PT inhibitors and respira-
tory chain inhibitors block Bax/Bak-induced, but not Bid/
Bik-induced, cytochrome c release (Shimizu and Tsuji-
moto, 2000). Based on these observations, we have pro-
posed that Bax/Bak target VDAC to induce cytochrome c
release, whereas Bid/Bik induces cytochrome c release by
a mechanism not involving the VDAC (Shimizu and
Tsujimoto, 2000; Tsujimoto and Shimizu, 2000b). Consis-
tently, we also showed here that VDAC is required for
Bax-induced, but not for Bid-induced, cytochrome c re-
lease and cell death. These results, together with our ob-
servation that Bax/Bak but not Bid/Bik induce cyto-
chrome  c release in mitochondria isolated from yeast cells
(unpublished observation), suggest that Bid/Bik probably
targets a distinct molecule on the mitochondrial outer
membrane to induce cytochrome c release (Fig. 8). It has
been suggested that Bid (tBid) exerts its activity by het-
erodimerizing with antiapoptotic members of the Bcl-2
family (Wang et al., 1996), or by facilitating oligomeriza-
tion of Bax and Bak to form pores permeable for cyto-
chrome c (Eskes et al., 2000; Wei et al., 2000). Bid (tBid)
has also been suggested to have an ability to form a pore
by itself (Schendel et al., 1999) or destabilizing lipid mem-
brane (Kudla et al., 2000). The substantial difference be-
tween Bax/Bak-induced and Bid/Bik-induced cytochrome
c release and apoptosis (Shimizu and Tsujimoto, 2000),
however, makes the possibility unlikely that Bid functions
only through heterodimerizing with Bcl-2/Bcl-xL or facili-
tating Bax/Bak oligomerization, because these two models
suggest no difference between Bid-induced and Bax/Bak-
induced cytochrome c release and cell death. The possibil-
ity is also unlikely that Bid/Bik forms a channel by itself or
destabilizes mitochondrial membrane for cytochrome c re-
lease, because, unlike Bax/Bak, Bid is unable to induce
cytochrome c release in yeast mitochondria (our unpub-
lished results). Since Bid/Bik-induced cytochrome c re-
lease is prevented by Bcl-2/Bcl-xL, these antiapoptotic
Bcl-2 family members might form heterodimers with Bid/
Bik to inhibit their activity or directly close the Bid/Bik
target channel in a similar manner as occurs with the
VDAC (Fig. 8).
In conclusion, we obtained evidence that the VDAC is
essential for Bax-induced (but not Bid-induced) apoptotic
cytochrome c release and apoptotic death and apoptosis
induced by etoposide, paclitaxel, and staurosporine in
mammalian cells. These results, taken together with our
previous observation that Bax opens the VDAC and re-
leases cytochrome c in a proteoliposome system (Shimizu
et al., 1999, 2000a), suggest that the VDAC is a channel for
apoptotic cytochrome c release that is directly regulated
by the Bcl-2 family of proteins.
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